Gynecologic Oncology

Tamoxifen, a common drug used to treat breast cancer, works by blocking the effect of estrogen on tumor cells.

Like the Deep South Network for Cancer Control, the Sowing the Seeds of Health program relies on community health advisors to spread the word about cancer prevention and early detection

New research suggested that concern about pain may deter obese women from undergoing mammography, while a busy schedule may dissuade women aged less than 60 years

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

New data suggest that immigration status may help explain why some women decide to be screened for cervical cancer and others do not

About 40% of insured women in the United States are not undergoing screening mammography at least every 2 years in keeping with guidelines from the USPSTF.

CYP2D6 phenotype status does not predict tamoxifen efficacy in patients with early-stage breast cancer, according to a retrospective analysis of data from the Breast International Group

Breast cancer researcher Edith A. Perez, MD, is aiming to present more detailed study findings at national conferences later this year that will help clinicians better identify patients who would benefit from HER2 targeted treatment.

It was 2 days after her very first mammogram when Lisa Vance got a call from her physician's office requesting that she come in to discuss the results. Even so, it never occurred to her to be worried.

Although several endocrine therapies are available today, the authors of this commentary contend that the quest for a better tamoxifen is ongoing.

Debu Tripathy, MD, Co-leader Women's Breast Cancer Program at USC/Norris Comprehensive Cancer Center, on bone health considerations for patients with breast cancer.

Debu Tripathy, MD, Co-leader Women’s Breast Cancer Program at USC/Norris Comprehensive Cancer Center, discusses clinical research and studies looking at the use of bisphosphonate for women with breast cancer.

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting

The shortage, which began in 2009, accelerated in 2010, and has shown no signs of abatement so far in 2011, according to Erin R. Fox, PharmD, manager of the Drug Information Service at University of Utah Health Care

The Emperor of All Maladies bills itself as a "biography of cancer," and while author Siddhartha Mukherjee cannot tell us precisely when cancer opened its eyes in this world...

Amid advances in gene-based cancer diagnostics, questions about the best use of molecular and cellular assays in practice are growing along with the new options for clinicians.

Useful Online Resources and Clinical Trials for Ovarian Cancer

The FDA has requested that the generic drug manufacturer Hospira change the planned label for its generic formulation of docetaxel.

The Internet has been employed in a variety of interesting ways to foster clinical or research agendas.

In the United States, gynecologic cancers affect nearly 80,000 women annually and are the cause of death in more than 25,000 women.

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.

In May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.

A false-positive result on a mammogram may trigger anxiety and decrease quality of life, and the effects may remain apparent a year later, new data suggest.

For women who have survived childhood cancer, breastfeeding may help counter some of the long-term complications that occur as a result of their prior cancer treatments, researchers say.

Everolimus (Afinitor) added to tamoxifen delayed tumor progression in patients with hormone receptor (HR)-positive, HER2-negative, advanced metastatic breast cancer